nach oben

psychopraxis. neuropraxis

Erschienen in:

14.04.2021 | Affektive Störungen | Psychiatrie

Verlauf und Therapie bipolarer Störungen

Module für die Gruppenpsychoedukation

verfasst von: Prim. Priv. Doz. Dr. Andreas Erfurth, Nikolaus Michael, Cornelia Roestel, Gabriele Sachs

Erschienen in: psychopraxis. neuropraxis | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Gruppenpsychoedukation ist ein wichtiges Element in der Behandlung von bipolaren Störungen. Ein Programm mit acht Sitzungen wird in dieser Zeitschrift „psychopraxis.neuropraxis“ beschrieben. Die vorliegende Publikation – die zweite von dreien – präsentiert die beiden Module, die dem Verlauf der Störung und den therapeutischen Möglichkeiten gewidmet sind. Es wird ein breiter Überblick über die einschlägige Literatur gegeben.

Erfurth A (Hrsg) (2003) Weißbuch Bipolare Störungen in Deutschland. Deutsche Gesellschaft für Bipolare Störungen e. V., . ISBN 3‑8311-4521‑0

Kasper S, Kapfhammer HP, Bach M, Butterfield-Meissl C, Erfurth A, Haring C, Hausmann A, Hofmann P, Kalousek M, Klier C, Marksteiner J, Mühlbacher M, Oberlerchner H, Psota G, Rados C, Sachs GM, Windhager E, Winkler J, Wrobel M (2013) Bipolare Störungen. CliniCum Neuropsy 2013(Sonderausgabe November):3–18

Joas E, Bäckman K, Karanti A, Sparding T, Colom F, Pålsson E, Landén M (2020) Psychoeducation for bipolar disorder and risk of recurrence and hospitalization—a within-individual analysis using registry data. Psychol Med 50(6):1043–1049. https://doi.org/10.1017/S0033291719001053CrossRefPubMed

Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, Torrent C, Comes M, Corbella B, Parramon G, Corominas J (2003) A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 60(4):402–407. https://doi.org/10.1001/archpsyc.60.4.402CrossRefPubMed

Schaub A, Bernhard B, Gauck L (2004) Kognitiv-psychoedukative Therapie bei bipolaren Erkrankungen. Ein Therapiemanual. Hogrefe, Göttingen. ISBN 978-3-8017-1838‑1

Erfurth A, Dobmeier G, Zechendorff M (2005) Kurzpsychoedukation für bipolare Patienten. Thieme, Stuttgart. ISBN 978-3-13-141681‑0

Erfurth A, Michael N, Roestel C, Sachs G (2021) Psychoedukation für bipolare Störungen – die prospektive Life-Chart-Methode. Psychoprax Neuroprax. https://doi.org/10.1007/s00739-020-00689-7CrossRef

Erfurth A, Arolt V (2003) Das Spektrum bipolarer Störungen. Nervenarzt 74(1):55–71. https://doi.org/10.1007/s00115-003-1473-xCrossRefPubMed

Erfurth A, Sachs G, Perugi G, Tondo L (2014) Athanasios Koukopoulos (1931–2013). Zum Verlauf manisch-depressiver Erkrankungen. Psychoprax Neuroprax 17:5–8. https://doi.org/10.1007/s00739-014-0172-7CrossRef

10.

Angst J, Merikangas KR, Cui L, Van Meter A, Ajdacic-Gross V, Rössler W (2018) Bipolar spectrum in major depressive disorders. Eur Arch Psychiatry Clin Neurosci 268(8):741–748. https://doi.org/10.1007/s00406-018-0927-xCrossRefPubMed

11.

American Psychiatric Association (2018) Diagnostisches und Statistisches Manual Psychischer Störungen DSM‑5 Bd. 2. Hogrefe, Göttingen (Deutsche Ausgabe herausgegeben von P. Falkai und H.-U. Wittchen, mitherausgegeben von M. Döpfner, W. Gaebel, W. Maier, W. Rief, H. Saß und M. Zaudig)

12.

Akiskal HS, Pinto O (1999) The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 22:517–534. https://doi.org/10.1016/s0193-953x(05)70093-9CrossRefPubMed

13.

Akiskal HS, Pinto O (2000) The soft bipolar spectrum: footnotes to Kraepelin on the interface of hypomania, temperament and depression. In: Marneros A, Angst J (Hrsg) Bipolar Disorders. Kluwer, Dordrecht, Boston, London, S 37–62. ISBN 978-0-7923-6588‑4

14.

Koukopoulos A, Reginaldi D, Tondo L, Visioli C, Baldessarini RJ (2013) Course sequences in bipolar disorder: depressions preceding or following manias or hypomanias. J Affect Disord 151(1):105–110. https://doi.org/10.1016/j.jad.2013.05.059CrossRefPubMed

15.

Hantouche EG, Erfurth A (2010) Rethinking subthreshold bipolarity: the rebirth of Kahlbaum-Hecker syndrome. Eur Psychiatr 25:170. https://doi.org/10.1016/S0924-9338(10)70170-XCrossRef

16.

Perugi G, Hantouche E, Vannucchi G, Pinto O (2015) Cyclothymia reloaded: a reappraisal of the most misconceived affective disorder. J Affect Disord 183:119–133. https://doi.org/10.1016/j.jad.2015.05.004CrossRefPubMed

17.

Perugi G, Hantouche E, Vannucchi G (2017) Diagnosis and treatment of cyclothymia: the “primacy” of temperament. Curr Neuropharmacol 15(3):372–379. https://doi.org/10.2174/1570159X14666160616120157CrossRefPubMedPubMedCentral

18.

Erfurth A, Sachs G (2015) Mischzustände, Mischbilder und die depressive Episode mit gemischten Merkmalen. Psychoprax Neuroprax 18(2):38–43. https://doi.org/10.1007/s00739-015-0241-6CrossRef

19.

Tortorella A, Albert U, Nivoli AMA, Erfurth A, Colom F, Maina G (2015) Mixed states: still a modern psychopathological syndrome? J Psychopathol 21:332–340

20.

Erfurth A, Perugi G (2005) Rapid cycling. In: Kasper S, Hirschfeld RMA (Hrsg) Handbook of Bipolar Disorder. Marcel Dekker, Taylor & Francis, New York, S 201–212

21.

Furio MA, Popovic D, Vieta E, Stukalin Y, Hagin M, Torrent C, Azorin JM, Angst J, Bowden CL, Mosolov S, Young AH, Perugi G, BRIDGE-II-Mix Study Group (2020) Characterization of rapid cycling bipolar patients presenting with major depressive episode within the BRIDGE-II-MIX study. Bipolar Disord. https://doi.org/10.1111/bdi.12994CrossRef

22.

Erfurth A, Gerlach AL, Hellweg I, Boenigk I, Michael N, Akiskal HS (2005) Studies on a German (Münster) version of the temperament auto-questionnaire TEMPS-A: construction and validation of the briefTEMPS‑M. J Affect Disord 85(1/2):53–69. https://doi.org/10.1016/S0165-0327(03)00102-2CrossRefPubMed

23.

Erfurth A, Gerlach AL, Michael N, Boenigk I, Hellweg I, Signoretta S, Akiskal K, Akiskal HS (2005) Distribution and gender effects of the subscales of a German version of the temperament autoquestionnaire briefTEMPS‑M in a university student population. J Affect Disord 85(1/2):71–76. https://doi.org/10.1016/j.jad.2003.07.003CrossRefPubMed

24.

Perugi G, Akiskal HS, Ramacciotti S, Nassini S, Toni C, Milanfranchi A, Musetti L (1999) Depressive comorbidity of panic, social phobic, and obsessive-compulsive disorders re-examined: is there a bipolar II connection? J Psychiatr Res 33(1):53–61. https://doi.org/10.1016/s0022-3956(98)00044-2CrossRefPubMed

25.

Perugi G, Erfurth A, Rihmer Z, Maremmani I, Brieger P (2005) Comorbidity in bipolar disorders. Eur Psychiatry 20:120

26.

Perugi G, Toni C, Akiskal HS (1999) Anxious-bipolar comorbidity. Diagnostic and treatment challenges. Psychiatr Clin North Am 22(3):565–583. https://doi.org/10.1016/s0193-953x(05)70096-4CrossRefPubMed

27.

Shahini M, Shala M, Xhylani P, Gashi S, Borinca I, Erfurth A (2018) Challenging predictions between affective temperaments, depression and anxiety in a Kosovo student community sample. Int J Psychiatry Clin Pract 22(4):282–288. https://doi.org/10.1080/13651501.2018.1426771CrossRefPubMed

28.

Schiele MA, Herzog K, Kollert L, Böhnlein J, Repple J, Rosenkranz, Leehr EJ, Ziegler C, Lueken U, Dannlowski U, Pauli P, Arolt V, Zwanzger P, Deckert J, Erfurth A, Domschke K (2020) Affective temperaments (TEMPS-A) in panic disorder and healthy probands: genetic modulation by 5‑HTT variation. World J Biol Psychiatry. https://doi.org/10.1080/15622975.2019.1705999CrossRefPubMed

29.

Erfurth A, Sachs G (2020) Angststörungen. In: Steiner M (Hrsg) Angst. WAS, Bd. 113. Leykam, Graz, Wien. ISBN 978-3-7011-8163‑6

30.

Mucci F, Toni C, Favaretto E, Vannucchi G, Marazziti D, Perugi G (2018) Obsessive-compulsive disorder with comorbid bipolar disorders: clinical features and treatment implications. Curr Med Chem 25(41):5722–5730. https://doi.org/10.2174/0929867324666171108145127CrossRefPubMed

31.

Sachs G, Erfurth A (2018) Obsessive compulsive and related disorders: from the biological basis to a rational pharmacological treatment. Int J Neuropsychopharmacol 21(1):59–62. https://doi.org/10.1093/ijnp/pyx101CrossRefPubMed

32.

Perugi G, Akiskal HS (2002) The soft bipolar spectrum redefined: focus on the cyclothymic, anxious-sensitive, impulse-dyscontrol, and binge-eating connection in bipolar II and related conditions. Psychiatr Clin North Am 25(4):713–737. https://doi.org/10.1016/s0193-953x(02)00023-0CrossRefPubMed

33.

Fornaro M, Perugi G, Gabrielli F, Prestia D, Mattei C, Vinciguerra V, Fornaro P (2010) Lifetime co-morbidity with different subtypes of eating disorders in 148 females with bipolar disorders. J Affect Disord 121(1/2):147–151. https://doi.org/10.1016/j.jad.2009.06.007CrossRefPubMed

34.

Azorin JM, Bowden CL, Garay RP, Perugi G, Vieta E, Young AH (2010) Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism. Neuropsychiatr Dis Treat 6:37–46. https://doi.org/10.2147/ndt.s6741CrossRefPubMedPubMedCentral

35.

Vyssoki B, Blüml V, Gleiss A, Friedrich F, Kogoj D, Walter H, Zeiler J, Höfer P, Lesch OM, Erfurth A (2011) The impact of temperament in the course of alcohol dependence. J Affect Disord 135(1-3):177–183. https://doi.org/10.1016/j.jad.2011.07.007CrossRefPubMed

36.

Maremmani I, Perugi G, Pacini M, Akiskal HS (2006) Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 93(1-3):1–12. https://doi.org/10.1016/j.jad.2006.02.022CrossRefPubMed

37.

Salem B, Vyssoki B, Lesch OM, Erfurth A (2014) Lesch typology and temperament in opioid dependence: a cross sectional study. J Affect Disord 165:203–207. https://doi.org/10.1016/j.jad.2014.04.066CrossRefPubMed

38.

Unseld M, Dworschak G, Tran US, Plener PL, Erfurth A, Walter H, Lesch OM, Kapusta ND (2012) The concept of temperament in psychoactive substance use among college students. J Affect Disord 141(2/3):324–330. https://doi.org/10.1016/j.jad.2012.03.028CrossRefPubMed

39.

Amann B, Padberg F, Mergl R, Naber D, Baghai T, Reimers K, El-Giamal N, Erfurth A, Laakmann G (2009) An investigation of temperamental traits in patients with somatoform disorder: do they belong in the affective spectrum? Psychosomatics 50(6):605–612. https://doi.org/10.1176/appi.psy.50.6.605CrossRefPubMed

40.

Nicholl BI, Mackay D, Cullen B, Martin DJ, Ul-Haq Z, Mair FS, Evans J, McIntosh AM, Gallagher J, Roberts B, Deary IJ, Pell JP, Smith DJ (2014) Chronic multisite pain in major depression and bipolar disorder: cross-sectional study of 149,611 participants in UK Biobank. BMC Psychiatry 14:350. https://doi.org/10.1186/s12888-014-0350-4CrossRefPubMedPubMedCentral

41.

Kasper S, Bach M, Sachs GM, Aigner M, Erfurth A, Glehr R, Konstantinidis A, Lehofer M, Löffler-Stastka H, Quasthoff S, Radoš C, Rießland-Seifert A, Windhager E (2015) Schmerz bei psychiatrischen Erkrankungen. Konsensus-Statement – State of the art. CliniCum Neuropsy 2015(Sonderausgabe November):3–23

42.

Masi G, Perugi G, Toni C, Millepiedi S, Mucci M, Bertini N, Pfanner C (2006) Attention-deficit hyperactivity disorder—bipolar comorbidity in children and adolescents. Bipolar Disord 8(4):373–381. https://doi.org/10.1111/j.1399-5618.2006.00342.xCrossRefPubMed

43.

Kutzelnigg A, Erfurth A, Kasper S (2007) Comorbidity of adult ADHD in patients with affective disorders and anxiety. J Neural Transm 114(7):LXVIII

44.

Skala K, Riegler A, Erfurth A, Völkl-Kernstock S, Lesch OM, Walter H (2016) The connection of temperament with ADHD occurrence and persistence into adulthood—An investigation in 18 year old males. J Affect Disord 198:72–77. https://doi.org/10.1016/j.jad.2016.03.051CrossRefPubMed

45.

Vannucchi G, Masi G, Toni C, Dell’Osso L, Erfurth A, Perugi G (2014) Bipolar disorder in adults with Asperger’s syndrome: a systematic review. J Affect Disord 168:151–160. https://doi.org/10.1016/j.jad.2014.06.042CrossRefPubMed

46.

Erfurth A, Evers S, Fischera M, Frese A, Gregor N, Heinrichs A (2007) Temperament evaluation in patients with migraine. Cephalalgia 27(6):587

47.

Fornaro M, De Berardis D, De Pasquale C, Indelicato L, Pollice R, Valchera A, Perna G, Iasevoli F, Tomasetti C, Martinotti G, Koshy AS, Fasmer OB, Oedegaard KJ (2015) Prevalence and clinical features associated to bipolar disorder-migraine comorbidity: a systematic review. Compr Psychiatry 56:1–16. https://doi.org/10.1016/j.comppsych.2014.09.020CrossRefPubMed

48.

Jamison KR (2000) Suicide and bipolar disorder. J Clin Psychiatry 61(Suppl 9):47–51PubMed

49.

Skala K, Kapusta ND, Schlaff G, Unseld M, Erfurth A, Lesch OM, Walter H, Akiskal KK, Akiskal HS (2012) Suicidal ideation and temperament: an investigation among college students. J Affect Disord 141(2-3):399–405. https://doi.org/10.1016/j.jad.2012.03.010CrossRefPubMed

50.

Perugi G, Quaranta G, Belletti S, Casalini F, Mosti N, Toni C, Dell’Osso L (2015) General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. J Affect Disord 170:95–103. https://doi.org/10.1016/j.jad.2014.08.052CrossRefPubMed

51.

Colomer L, Anmella G, Vieta E, Grande I (2020) Physical health in affective disorders: a narrative review of the literature. Braz J Psychiatry. https://doi.org/10.1590/1516-4446-2020-1246CrossRefPubMed

52.

Epiktet (2014) Handbüchlein der Moral. Philipp Reclam jun, Stuttgart. ISBN 978-3-15-019103‑3 (Aus dem Griechischen übersetzt von Kurt Steinmann)

53.

Sartre JP (2000) Der Existentialismus ein Humanismus. Deutsche Übersetzung von Vincent von Wroblewsky. In: Sartre JP (Hrsg) Der Existenzialismus ist ein Humanismus. Und andere philosophische Essays 1943–1948. Rowohlt, Reinbek

54.

Lazarus RS (1993) From psychological stress to the emotions: a history of changing outlooks. Annu Rev Psychol 44(1):1–22. https://doi.org/10.1146/annurev.ps.44.020193.000245CrossRefPubMed

55.

Ingram RE, Luxton DD (2005) Vulnerability-stress models. In: Hankin BL, Abela JRZ (Hrsg) Development of psychopathology: a vulnerability stress perspective. SAGE, Thousand Oaks, S 32–46CrossRef

56.

Belsky J, Pluess M (2009) Beyond diathesis stress: differential susceptibility to environmental influences. Psychol Bull 135(6):885–908. https://doi.org/10.1037/a0017376CrossRefPubMed

57.

Scott J (1995) Psychotherapy for bipolar disorder. Br J Psychiatry 167(5):581–588. https://doi.org/10.1192/bjp.167.5.581CrossRefPubMed

58.

Frank E, Swart HA, Mallinger AG, Thase ME, Weaver EV, Kupfer DJ (1999) Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol 108(4):579–587. https://doi.org/10.1037//0021-843x.108.4.579CrossRefPubMed

59.

Miklowitz DJ (2008) Adjunctive psychotherapy for bipolar disorder: state of the evidence. Am J Psychiatry 165(11):1408–1419. https://doi.org/10.1176/appi.ajp.2008.08040488CrossRefPubMedPubMedCentral

60.

Schöttle D, Huber CG, Bock T, Meyer TD (2011) Psychotherapy for bipolar disorder: a review of the most recent studies. Curr Opin Psychiatry 24(6):549–555. https://doi.org/10.1097/YCO.0b013e32834b7c5fCrossRefPubMed

61.

Erfurth A, Sachs G (2018) Bipolare Störungen – Ein Update. Psychoprax Neuroprax 21(3):123–127. https://doi.org/10.1007/s00739-018-0470-6CrossRef

62.

Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR, Cipriani A (2020) Adjunctive psychotherapy for bipolar disorder: a systematic review and component network meta-analysis. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2020.2993CrossRefPubMedPubMedCentral

63.

Panhorst H, Ramacher P, Wagener R, Erfurth A (2001) Psychoedukation bei bipolaren Störungen. Nervenheilkunde 20(Suppl. 2):34–38

64.

Bond K, Anderson IM (2015) Psychoeducation for relapse prevention in bipolar disorder: a systematic review of efficacy in randomized controlled trials. Bipolar Disord 17(4):349–362. https://doi.org/10.1111/bdi.12287CrossRefPubMed

65.

Huxley NA, Parikh SV, Baldessarini RJ (2000) Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry 8(3):126–140CrossRef

66.

Alloy LB, Abramson LY, Urosevic S, Walshaw PD, Nusslock R, Neeren AM (2005) The psychosocial context of bipolar disorder: environmental, cognitive, and developmental risk factors. Clin Psychol Rev 25(8):1043–1075. https://doi.org/10.1016/j.cpr.2005.06.006CrossRefPubMed

67.

Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR (2008) Psychosocial interventions for the prevention of relapse in bipolar disorder: systematic review of controlled trials. Br J Psychiatry 192(1):5–11. https://doi.org/10.1192/bjp.bp.107.037887CrossRefPubMed

68.

Sachs GM, Pintsov O, Winklbaur B, Erfurth A, Lenz G, Thau K (2008) Neurocognitive functions as endophenotypes in schizophrenia and bipolar disorder. Eur Psychiatr 23:S142. https://doi.org/10.1016/j.eurpsy.2008.01.876CrossRef

69.

Harvey PD, Wingo AP, Burdick KE, Baldessarini RJ (2010) Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord 12(4):364–375. https://doi.org/10.1111/j.1399-5618.2010.00831.xCrossRefPubMed

70.

Sachs G, Erfurth A (2015) Kognition bei depressiven Störungen. Psychoprax Neuroprax 18(5):172–179. https://doi.org/10.1007/s00739-015-0281-yCrossRef

71.

Demant KM, Vinberg M, Kessing LV, Miskowiak KW (2015) Effects of short-term cognitive remediation on cognitive dysfunction in partially or fully remitted individuals with bipolar disorder: results of a randomised controlled trial. Plos One 10(6):e127955. https://doi.org/10.1371/journal.pone.0127955CrossRefPubMedPubMedCentral

72.

Veeh J, Kopf J, Kittel-Schneider S, Deckert J, Reif A (2017) Cognitive remediation for bipolar patients with objective cognitive impairment: a naturalistic study. Int J Bipolar Disord 5(1):8. https://doi.org/10.1186/s40345-017-0079-3CrossRefPubMedPubMedCentral

73.

Sachs G, Maihofer E, Swoboda H, Berg A, Lasser I, Lenz G, Erfurth A (2018) Cognitive dysfunction and remediation in affective disorders. Eur Psychiatr 48:S46. https://doi.org/10.1016/j.eurpsy.2017.12.013CrossRef

74.

Sachs G, Berg A, Jagsch R, Lenz G, Erfurth A (2020) Predictors of functional outcome in patients with bipolar disorder: effects of cognitive psychoeducational group therapy after 12 months. Front Psychiatry. https://doi.org/10.3389/fpsyt.2020.530026CrossRefPubMedPubMedCentral

75.

Cade JF (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust 2(10):349–352. https://doi.org/10.1080/j.1440-1614.1999.06241.xCrossRefPubMed

76.

Schou M, Juel-Nielsen N, Strögren E, Voldby H (1954) The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 17(4):250–260. https://doi.org/10.1136/jnnp.17.4.250CrossRefPubMedPubMedCentral

77.

Baastrup PC, Schou M (1967) Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 16(2):162–172. https://doi.org/10.1001/archpsyc.1967.01730200030005CrossRefPubMed

78.

Angst J, Weis P, Grof P, Baastrup PC, Schou M (1970) Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 116(535):604–614. https://doi.org/10.1192/bjp.116.535.604CrossRefPubMed

79.

Kukopulos A, Reginaldi D (1973) Does lithium prevent depressions by suppressing manias? Int Pharmacopsychiatry 8(3):152–158. https://doi.org/10.1159/000467986CrossRefPubMed

80.

Kukopulos A, Reginaldi D, Girardi P, Tondo L (1975) Course of manic-depressive recurrences under lithium. Compr Psychiatry 16(6):517–524. https://doi.org/10.1016/s0010-440x(75)80014-9CrossRefPubMed

81.

Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1997) Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomised study. J Affect Disord 43(2):151–161. https://doi.org/10.1016/s0165-0327(96)01427-9CrossRefPubMed

82.

Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B (1998) Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 18(6):455–460. https://doi.org/10.1097/00004714-199812000-00007CrossRefPubMed

83.

Schou M (1999) Perspectives on lithium treatment of bipolar disorder: action, efficacy, effect on suicidal behavior. Bipolar Disord 1(1):5–10. https://doi.org/10.1034/j.1399-5618.1999.10103.xCrossRefPubMed

84.

Kleindienst N, Severus WE, Greil W (2007) Are serum lithium levels related to the polarity of recurrence in bipolar disorders? Evidence from a multicenter trial. Int Clin Psychopharmacol 22(3):125–131. https://doi.org/10.1097/01.yic.0000224788.21406.c8CrossRefPubMed

85.

Coryell W (2009) Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord 11(Suppl 2):77–83. https://doi.org/10.1111/j.1399-5618.2009.00712.xCrossRefPubMed

86.

Grof P, Müller-Oerlinghausen B (2009) A critical appraisal of lithium’s efficacy and effectiveness: the last 60 years. Bipolar Disord 11(Suppl 2):10–19. https://doi.org/10.1111/j.1399-5618.2009.00707.xCrossRefPubMed

87.

Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W (1996) Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 29(3):103–107. https://doi.org/10.1055/s-2007-979553CrossRefPubMed

88.

Tondo L, Jamison KR, Baldessarini RJ (1997) Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann N Y Acad Sci 836:339–351. https://doi.org/10.1111/j.1749-6632.1997.tb52369.xCrossRefPubMed

89.

Müller-Oerlinghausen B (2001) Arguments for the specificity of the antisuicidal effect of lithium. Eur Arch Psychiatry Clin Neurosci 251(Suppl 2):II72–II75. https://doi.org/10.1007/BF03035132CrossRefPubMed

90.

Tondo L, Hennen J, Baldessarini RJ (2001) Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 104(3):163–172. https://doi.org/10.1034/j.1600-0447.2001.00464.xCrossRefPubMed

91.

Tondo L, Baldessarini RJ (2018) Antisuicidal effects in mood disorders: are they unique to lithium? Pharmacopsychiatry 51(5):177–188. https://doi.org/10.1055/a-0596-7853CrossRefPubMed

92.

Emrich HM, Dose M, von Zerssen D (1985) The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 8(3):243–250. https://doi.org/10.1016/0165-0327(85)90022-9CrossRefPubMed

93.

Grunze H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J (1999) Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol 19(4):303–309. https://doi.org/10.1097/00004714-199908000-00003CrossRefPubMed

94.

Cipriani A, Reid K, Young AH, Macritchie K, Geddes J (2013) Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003196.pub2CrossRefPubMedPubMedCentral

95.

Erfurth A, Walden J, Grunze H (1998) Lamotrigine in the treatment of schizoaffective disorder. Neuropsychobiology 38(3):204–205. https://doi.org/10.1159/000026540CrossRefPubMed

96.

Calabrese JR, Vieta E, Shelton MD (2003) Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 13(Suppl 2):S57–S66. https://doi.org/10.1016/s0924-977x(03)00079-8CrossRefPubMed

97.

Hahn CG, Gyulai L, Baldassano CF, Lenox RH (2004) The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry 65(6):791–804. https://doi.org/10.4088/jcp.v65n0610CrossRefPubMed

98.

Muzina DJ, Elhaj O, Gajwani P, Gao K, Calabrese JR (2005) Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr Scand Suppl 426:21–28. https://doi.org/10.1111/j.1600-0447.2005.00523.xCrossRef

99.

Hirschfeld RM, Kasper S (2004) A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 7(4):507–522. https://doi.org/10.1017/S1461145704004651CrossRefPubMed

100.

Dietrich DE, Kropp S, Emrich HM (2003) Oxcarbazepine in the treatment of affective and schizoaffective disorders. Fortschr Neurol Psychiatr 71(5):255–264. https://doi.org/10.1055/s-2003-39065CrossRefPubMed

101.

Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH (2011) Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004857.pub2CrossRefPubMed

102.

Erfurth A, Kammerer C, Grunze H, Normann C, Walden J (1998) An open label study of gabapentin in the treatment of acute mania. J Psychiatr Res 32(5):261–264. https://doi.org/10.1016/S0022-3956(98)00010-7CrossRefPubMed

103.

Altshuler LL, Keck PE Jr, McElroy SL, Suppes T, Brown ES, Denicoff K, Frye M, Gitlin M, Hwang S, Goodman R, Leverich G, Nolen W, Kupka R, Post R (1999) Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1(1):61–65. https://doi.org/10.1034/j.1399-5618.1999.10113.xCrossRefPubMed

104.

Vieta E, Martinez-Arán A, Nieto E, Colom F, Reinares M, Benabarre A, Gastó C (2000) Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 15(7):433–437. https://doi.org/10.1016/s0924-9338(00)00514-9CrossRefPubMed

105.

Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA (2002) Gabapentin augmentation therapy in bipolar depression. Bipolar Disord 4(5):296–301. https://doi.org/10.1034/j.1399-5618.2002.01211.xCrossRefPubMed

106.

Perugi G, Toni C, Frare F, Ruffolo G, Moretti L, Torti C, Akiskal HS (2002) Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol 22(6):584–591. https://doi.org/10.1097/00004714-200212000-00008CrossRefPubMed

107.

Houghton KT, Forrest A, Awad A, Atkinson LZ, Stockton S, Harrison PJ, Geddes JR, Cipriani A (2017) Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. BMJ Open 7(3):e13433. https://doi.org/10.1136/bmjopen-2016-013433CrossRefPubMedPubMedCentral

108.

Schaffer LC, Schaffer CB, Miller AR, Manley JL, Piekut JA, Nordahl TE (2013) An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. J Affect Disord 147(1/3):407–410. https://doi.org/10.1016/j.jad.2012.09.005CrossRefPubMed

109.

Erfurth A, Kuhn G (2000) Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids. Neuropsychobiology 42(Suppl 1):50–51. https://doi.org/10.1159/000054854CrossRefPubMed

110.

Pecuch PW, Erfurth A (2001) Topiramate in the treatment of acute mania. J Clin Psychopharmacol 21(2):243–244. https://doi.org/10.1097/00004714-200104000-00022CrossRefPubMed

111.

Chengappa KN, Gershon S, Levine J (2001) The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 3(5):215–232CrossRef

112.

Erfurth A, Grunze H (1998) New perspectives in the treatment of acute mania: a single case report. Prog Neuropsychopharmacol Biol Psychiatry 22(6):1053–1059. https://doi.org/10.1016/s0278-5846(98)00061-xCrossRefPubMed

113.

Grunze H, Erfurth A, Schäfer M, Amann B, Meyendorf R (1999) Elektrokonvulsionstherapie in der Behandlung der schweren Manie – Kasuistik und Wissensstand. Nervenarzt 70(7):662–667. https://doi.org/10.1007/s001150050493CrossRefPubMed

114.

Erfurth A, Michael N, Mostert C, Arolt V (2000) Euphoric mania and rapid transcranial magnetic stimulation. Am J Psychiatry 157(5):835–836. https://doi.org/10.1176/appi.ajp.157.5.835-aCrossRefPubMed

115.

Michael N, Erfurth A (2004) Treatment of bipolar mania with right prefrontal rapid transcranial magnetic stimulation. J Affect Disord 78(3):253–257. https://doi.org/10.1016/S0165-0327(02)00308-7CrossRefPubMed

116.

Erfurth A, Michael N, Arolt V (2001) Therapie der bipolaren Depression. Nervenheilkunde 20(Suppl. 2):7–10

117.

Michael N, Erfurth A, Arolt V (2001) Elektrokrampftherapie und transkranielle Magnetstimulation zur Behandlung bipolarer Störungen. Nervenheilkunde 20(Suppl. 2):30–33

118.

Erfurth A, Michael N, Grunze H, Walden J (2001) Behandlung affektiver Mischzustände und des “rapid cycling” – Alternativen zur Lithiumtherapie. Nervenheilkunde 20(Suppl. 2):39–40

119.

Erfurth A, Sachs G (2017) Aggression und serotoninerge Dysfunktion: Neurochemische Befunde und Therapiemöglichkeiten. Psychoprax Neuroprax 20(1):23–27. https://doi.org/10.1007/s00739-016-0366-2CrossRef

120.

Erfurth A (2017) Agitation: a central challenge in psychiatry. World J Biol Psychiatry 18(1):3–4. https://doi.org/10.1080/15622975.2016.1237043CrossRefPubMed

121.

Amodeo G, Fagiolini A, Sachs G, Erfurth A (2017) Older and newer strategies for the pharmacological treatment of agitation in schizophrenia and bipolar disorder. CNS Neurol Disord Drug Targets 16(8):885–890. https://doi.org/10.2174/1871527316666170919115507CrossRefPubMed

122.

Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L (1980) Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 13(4):156–167. https://doi.org/10.1055/s-2007-1019628CrossRefPubMed

123.

Reginaldi D, Tondo L, Floris G, Pignatelli A, Kukopulos A (1981) Poor prophylactic lithium response due to antidepressants. Int Pharmacopsychiatry 16(2):124–128. https://doi.org/10.1159/000468484CrossRefPubMed

124.

Reginaldi D, Tondo L, Caliari B, Minnai GP, Kukopulos A (1982) The role of antidepressants in rapid cyclicity. Adv Biochem Psychopharmacol 32:363–367PubMed

125.

Perugi G, Pacchiarotti I, Mainardi C, Verdolini N, Menculini G, Barbuti M, Angst J, Azorin JM, Bowden CL, Mosolov S, Young AH, Vieta E, BRIDGE-II-MIX Study Group (2019) Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis. Eur Neuropsychopharmacol 29(7):825–834. https://doi.org/10.1016/j.euroneuro.2019.06.001CrossRefPubMed

126.

Novak W, Erfurth A (2017) Therapie depressiver Störungen mit selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI). Psychoprax Neuroprax 20(1):28–41. https://doi.org/10.1007/s00739-016-0371-5CrossRef

127.

Novak W, Sachs G, Erfurth A (2017) Diagnostik und Therapie depressiver Störungen. 1. Teil. Psychoprax Neuroprax 20(2):60–65. https://doi.org/10.1007/s00739-017-0378-6CrossRef

128.

Novak W, Sachs G, Erfurth A (2017) Diagnostik und Therapie depressiver Störungen. 2. Teil. Psychoprax Neuroprax 20(3):124–129. https://doi.org/10.1007/s00739-017-0389-3CrossRef

129.

Himmelhoch JM, Thase ME, Mallinger AG, Houck P (1991) Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148(7):910–916. https://doi.org/10.1176/ajp.148.7.910CrossRefPubMed

130.

Thase ME (2012) The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry 73(Suppl 1):10–16. https://doi.org/10.4088/JCP.11096su1c.02CrossRefPubMed

131.

Schmauss M, Erfurth A (1989) Indikationen für eine Therapie mit MAO-Hemmern. Psychiatr Prax 16(Suppl 1):2–6PubMed

132.

Erfurth A, Michael N, Stadtland C, Arolt V (2002) Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology 45(Suppl 1):33–36. https://doi.org/10.1159/000049259CrossRefPubMed

133.

Erfurth A (2016) Milnacipran. Ein neuer Serotonin-Noradrenalin-Wiederaufnahmehemmer bereichert die antidepressive Therapie. Thieme Drug Rep 18:4–12

134.

Schmauss M, Erfurth A (1996) Kombinationstherapien bei Therapieresistenz auf Antidepressiva: eine Übersicht. Fortschr Neurol Psychiatr 64(10):390–402. https://doi.org/10.1055/s-2007-996583CrossRefPubMed

135.

Erfurth A, Möller HJ (2000) Vorgehen bei Antidepressiva-Nonrespondern. In: Möller HJ (Hrsg) Therapie psychiatrischer Erkrankungen, 2. Aufl. Thieme, Stuttgart, S 407–413. ISBN 3‑432-99651‑9

136.

Köhnlein O, Lutz R, Erfurth A, Messer T, Hiemke C, Schmauss M (2004) Therapeutisches Drug Monitoring: Wann macht es in der Praxis Sinn? Neurol & Psychiater 12:46–50

137.

Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51(e1):1–2. https://doi.org/10.1055/s-0037-1600991CrossRef

138.

Erfurth A, Konstantinidis A (2008) Polypharmacy in bipolar disorder: does it make sense? Ann Gen Psychiatry 7(1):48. https://doi.org/10.1186/1744-859X-7-S1-S48CrossRef

139.

Adachi N, Azekawa T, Edagawa K, Goto E, Hongo S, Kato M, Katsumoto E, Kikuchi T, Kubota Y, Miki K, Nakagawa A, Tsuboi T, Ueda H, Watanabe K, Watanabe Y, Yasui-Furukori N, Yoshimura R (2020) Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients’ and practitioners’ parameters in the MUSUBI study. Hum Psychopharmacol 22:e2764. https://doi.org/10.1002/hup.2764CrossRef

140.

Nasrallah HA, Churchill CM, Hamdan-Allan GA (1988) Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 145(11):1455–1456. https://doi.org/10.1176/ajp.145.11.1455CrossRefPubMed

141.

Grohmann R, Koch R, Schmidt LG (1990) Extrapyramidal symptoms in neuroleptic recipients. Agents Actions Suppl 29:71–82. https://doi.org/10.1007/978-3-0348-7292-8_7CrossRefPubMed

142.

Michael N, Sourgens H, Arolt V, Erfurth A (2002) Severe tardive dyskinesia in affective disorders: treatment with vitamin E and C. Neuropsychobiology 46(Suppl 1):28–30. https://doi.org/10.1159/000068019CrossRefPubMed

143.

Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR (2008) Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 28(2):203–209. https://doi.org/10.1097/JCP.0b013e318166c4d5CrossRefPubMedPubMedCentral

144.

Erfurth A, Amann B, Grunze H (1998) Female genital disorder as adverse symptom of lamotrigine treatment. A serotoninergic effect? Neuropsychobiology 38(3):200–201. https://doi.org/10.1159/000026538CrossRefPubMed

145.

Cohen S, Kühn KU, Bender S, Erfurth A, Gastpar M, Murafi A, Rothermundt M, Signerski J, Sträter B, Teusch L, Weig W, Welling A, Westheide J, Huber TJ (2007) Sexual impairment in psychiatric inpatients: focus on depression. Pharmacopsychiatry 40(2):58–63. https://doi.org/10.1055/s-2007-970143CrossRefPubMed

146.

Westheide J, Cohen S, Bender S, Cooper-Mahkorn D, Erfurth A, Gastpar M, Huber TJ, Maier W, Murafi A, Rothermundt M, Signerski J, Sträter B, Teusch L, Weig W, Welling A, Kühn KU (2007) Sexual dysfunction in psychiatric inpatients the role of antipsychotic medication. Pharmacopsychiatry 40(4):140–145. https://doi.org/10.1055/s-2007-981480CrossRefPubMed

147.

García-Blanco A, García-Portilla MP, Fuente-Tomás L, Batalla M, Sánchez-Autet M, Arranz B, Safont G, Arqués S, Livianos L, Sierra P (2020) Sexual dysfunction and mood stabilizers in long-term stable patients with bipolar disorder. J Sex Med 17(5):930–940. https://doi.org/10.1016/j.jsxm.2020.01.032CrossRefPubMed

148.

Barton BB, Zagler A, Engl K, Rihs L, Musil R (2020) Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in Psychiatry (MiP) Study. Eur Arch Psychiatry Clin Neurosci 270(5):597–609. https://doi.org/10.1007/s00406-019-01043-8CrossRefPubMed

149.

Bai Y, Yang H, Chen G, Gao K (2020) Acceptability of acute and maintenance pharmacotherapy of bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled clinical trials. J Clin Psychopharmacol 40(2):167–179CrossRef

150.

Klein CC, Topalian AG, Starr B, Welge J, Blom T, Starr C, Deetz I, Turner H, Sage J, Utecht J, Fornari V, Patino Duran L, Higdon C, Sutton JJ, Sorter MT, Correll CU, DelBello MP (2020) The importance of second-generation antipsychotic-related weight gain and adherence barriers in youth with bipolar disorders: patient, parent, and provider perspectives. J Child Adolesc Psychopharmacol 30(6):376–380. https://doi.org/10.1089/cap.2019.0184CrossRefPubMed

151.

Nielsen RE, Banner J, Jensen SE (2020) Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol. https://doi.org/10.1038/s41569-020-00463-7CrossRefPubMed

Titel: Verlauf und Therapie bipolarer Störungen
Module für die Gruppenpsychoedukation
verfasst von: Prim. Priv. Doz. Dr. Andreas Erfurth
Nikolaus Michael
Cornelia Roestel
Gabriele Sachs
Publikationsdatum: 14.04.2021
Verlag: Springer Vienna
Schlagwörter: Affektive Störungen
Affektive Störungen
Erschienen in: psychopraxis. neuropraxis / Ausgabe 3/2021
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI: https://doi.org/10.1007/s00739-021-00718-z

Passend zum Thema

Mittelgradige Depressionen & Johanniskraut: Das hat sich geändert

Affektive Störungen

Die Behandlungsempfehlungen bei mittelgradiger Depression wurden erneuert und der Einsatz von Johanniskraut entscheidend präzisiert – welche zwei Empfehlungen Sie aus der aktualisierten Depressions-Leitlinie jetzt kennen sollten.

3 Kernaussagen: Cochrane-Analyse untersucht Johanniskrautextrakte

Affektive Störungen

Johanniskraut gehört zu den am besten untersuchten pflanzlichen Arzneimitteln. Die Ergebnisse zur Wirksamkeit bei Depressionen wurden u. a. in einem Cochrane-Review analysiert [1]. Wie das pflanzliche Antidepressivum dabei abschnitt und welche drei Kernaussagen Sie für die Praxis kennen sollten, lesen Sie hier.

Depression behandeln. Natürlich.

Content Hub

Aktuelle Ergebnisse aus in-vitro- und in-vivo-Untersuchungen liefern detaillierte Erklärungen zum Wirkmechanismus von hochdosiertem Johanniskraut-Extrakt: Neu ist die Erkenntnis, dass der Johanniskraut-Extrakt bei chronischem Stress die deregulierte Stressantwort der überaktiven HPA-Achse sowie die Expression des Stressgens FKBP5 normalisieren kann. Mehr zum aktuellen Stand der Wissenschaft bei der Therapie von Depressionen erfahren Sie hier.

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

COVID-19-Risiko bei Demenzkranken verdoppelt

Panorama

Suizidwunsch steigt nach MCI- und Demenzdiagnose

Schlafstörungen und COVID-19-Erkrankung

Immunmediierte Bewegungsstörungen

Parkinson oder nicht? L-Dopa-Antwort nicht sehr aussagekräftig

Passend zum Thema

Mittelgradige Depressionen & Johanniskraut: Das hat sich geändert

3 Kernaussagen: Cochrane-Analyse untersucht Johanniskrautextrakte

Depression behandeln. Natürlich.